A model for the return and referral of all clinically significant secondary findings of genomic sequencing

Genomic sequencing (GS) has the capability of identifying a broad range of clinically significant secondary findings (SFs) beyond medically actionable findings. Healthcare resources and capacity constraints of returning and managing all clinically significant SFs represent major barriers to implementation of GS. We present a model for the return and referral of all clinically significant SFs initially identified in the research setting and transitioned into clinical care. By involving multiple healthcare providers (HCPs), this process aimed to decrease the burden on a single HCP to manage all of a patients’ SFs. Efficient and scalable models are fundamental to facilitate the uptake of GS and advance precision medicine. (By Rita Kodida, MS, CCGC, CGC, https://jmg.bmj.com/content/early/2023/05/22/jmg-2022-109091 )

(Visited 101 times, 1 visits today)